Personalis Bets on Scale Despite Near-Term Losses

Personalis ((PSNL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Personalis’ latest earnings call struck a confident yet candid tone, pairing eye‑catching growth in its core clinical testing business with a frank acknowledgment of near‑term financial strain. Management emphasized that surging volumes, new Medicare coverage and strong biopharma demand justify higher losses today, framing this as a deliberate bet on future reimbursement, margins and market share.

Explosive Clinical Volume Growth

Personalis highlighted a breakout year for its NeXT Personal clinical tests, delivering 6,183 tests in Q4 2025, up 41% sequentially and 329% year over year. For 2025, volumes topped 16,000 tests, a 394% jump, and the company now targets 43,000–45,000 tests in 2026, implying about 170% growth and an ambition to roughly quadruple clinical volumes again.

Substantial MRD Biopharma Momentum

Minimal residual disease biopharma revenue surged nearly 240% year over year in 2025, underscoring strong demand from drug developers even as total biopharma revenue slipped slightly to $49 million on expected trial wind‑downs. For 2026, Personalis projects MRD biopharma revenue of $20–21 million and expects “strategic revenue” to more than double to $30–32 million as new projects ramp.

Medicare Coverage Wins

The company secured two important Medicare coverage decisions, for breast cancer and lung cancer surveillance, both at favorable pricing levels that unlock an initial reimbursed revenue stream. Management said these wins boost the legitimacy of NeXT Personal in the market, while a separate IO monitoring dossier is under review and could further expand reimbursed indications.

Strong Cash and Liquidity Position

Personalis ended Q4 2025 with about $240 million in cash and short‑term investments and only minor equipment‑related debt, giving it meaningful financial flexibility. After using roughly $74 million of cash in 2025, the company plans to step up cash usage to about $100 million in 2026 to fund aggressive scaling, implying roughly two and a half years of runway at current burn.

Product Innovation and Robust Evidence Base

On the product side, Personalis rolled out a real‑time variant tracker module as an opt‑in feature for NeXT Personal, with early access customers responding positively. Management also pointed to a growing body of clinical evidence, citing landmark studies such as TRACERx and UCSD I‑PREDICT plus more than 35 ongoing trials, including B‑STRONGER‑1 with over 200 patients enrolled, to support adoption and reimbursement.

Commercial Traction and Partnerships

Commercially, more than 900 oncologists are now ordering NeXT Personal, demonstrating broad awareness and early traction across community and academic settings. The company expanded its partnership with Tempus to cover colorectal cancer and plans to roughly double its 10‑rep sales force, aiming to deepen usage within existing accounts and accelerate new site activation.

Transitional Top-Line Impact from Legacy Contract Wind-Downs

Despite booming clinical volumes, headline revenue growth remained muted as Personalis absorbed the wind‑down of legacy contracts. Full‑year 2025 revenue was $69.6 million, held back by about $29 million of expected headwinds from a Natera contract decline and the end of a Moderna melanoma trial, leaving Q4 revenue up just 3% year over year at $17.3 million.

Gross Margin Compression from Unreimbursed Volume

Gross margin deteriorated to 11% in Q4 2025 and 22.7% for the full year, with management blaming heavy dilution from unreimbursed NeXT Personal testing. They estimated Q4 margins were hit by roughly 1,900 basis points due to this factor and cautioned that pressure will likely persist into early 2026 until additional coverage decisions allow more of today’s volume to convert into recognized revenue.

Rising Net Loss and Increased Cash Burn

Net loss widened to $23.8 million in Q4 2025 from $16.4 million a year earlier, while full‑year net loss held roughly flat at $81.3 million as spending ramped alongside growth. Looking ahead, Personalis expects 2026 net loss to expand to about $105 million and cash usage to rise to roughly $100 million, reflecting heavier investments in sales, infrastructure and clinical evidence.

Significant Portion of Tests Currently Unreimbursed

Management noted that less than half of NeXT Personal tests run today are in reimbursed indications, leaving a large share of “zero” revenue tests that weigh on margins. Medicare patients make up about half of total volume, but only part of that is fee‑for‑service under existing coverage, underscoring the company’s heavy reliance on future reimbursement wins to unlock the economic value of its current throughput.

Biopharma Revenue Variability and Project Timing Risk

While MRD biopharma grew sharply, overall biopharma revenue remains lumpy due to project‑based work and shifting pharma budgets, with Q4 biopharma revenue slipping to $10.9 million from $12.2 million a year ago. Full‑year biopharma revenue of $49 million was down slightly from 2024 as major trials wrapped up, highlighting timing risk even as the company pursues a deeper pipeline of collaborations.

Operating Expense Increase

Operating expenses rose to $27.2 million in Q4 2025 from $22.7 million in the prior year, reaching $103.8 million for the full year compared with $95.1 million in 2024. The company attributed the increase to commercial expansion and ongoing R&D and evidence‑generation efforts, which add pressure to near‑term profitability but are positioned as critical to scaling the franchise.

Guidance and Forward-Looking Outlook

For 2026, Personalis guided total revenue of $78–80 million, including $10–11 million of clinical revenue tied largely to new Medicare indications and $55–56 million from pharma tests and other services plus about $13 million from population sequencing and enterprise work. It projects 43,000–45,000 NeXT Personal tests, strategic revenue more than doubling, gross margin improving modestly to 15–20% and a net loss of around $105 million alongside roughly $100 million of cash usage.

Personalis’ earnings call painted a picture of a company in aggressive build‑out mode, trading near‑term profitability for scale in a fast‑emerging cancer monitoring market. With rapid test growth, solid cash reserves and growing Medicare and biopharma validation, investors will be watching whether new coverage decisions and biopharma demand arrive quickly enough to turn today’s high‑volume, low‑margin profile into a more sustainable, higher‑margin business.